BNP Secretary General Mirza Fakhrul Islam Alamgir has accused the government of jeopardizing Bangladesh’s pharmaceutical industry through opaque and one-sided policies. In a statement, Fakhrul said no new drug registrations have been issued in nearly two years, and medicine prices have not been adjusted for an extended period — putting the country at risk of losing its TRIPS waiver benefits when Bangladesh graduates to middle-income status on November 24, 2026. He criticized the exclusion of Bangladesh Association of Pharmaceutical Industries representatives from key drug regulation committees, calling it against the sector’s interests. Fakhrul urged swift action to protect the industry, taking into account the post-LDC graduation scenario, and highlighted the BNP government’s past role in strengthening the sector.